NCT05963334View on ClinicalTrials.gov

Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

November 30, 2019

Study Completion Date

June 6, 2023

Conditions
Advanced Epithelial Ovarian Cancer
Interventions
DRUG

Carboplatin/paclitaxel

Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.

Trial Locations (1)

12613

Pharmacology and toxicology department, Faculty of Pharmacy, Cairo University., Cairo

All Listed Sponsors
collaborator

Misr International University

OTHER

lead

Cairo University

OTHER

NCT05963334 - Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter